lamivudine / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 64 Diseases   29 Trials   29 Trials   2746 News 


12345678910111213...3536»
  • ||||||||||  Dovato (dolutegravir/lamivudine) / ViiV Healthcare, Tivicay (dolutegravir) / ViiV Healthcare
    Journal:  'With age comes wisdom': effectiveness and tolerability of dolutegravir + lamivudine in virologically-suppressed people with HIV. (Pubmed Central) -  May 29, 2025   
    Our results indicate that simultaneous initiation of 3HP tuberculosis preventive treatment and dolutegravir-based ART was safe and achieved therapeutic concentrations among antiretroviral-naive individuals with HIV, and dolutegravir dose adjustments are not needed. Our findings confirm the long-term effectiveness and tolerability of dolutegravir plus lamivudine in virologically suppressed PWH.
  • ||||||||||  Pricing, Journal:  A global comparison of hepatitis B & C drug pricing. (Pubmed Central) -  May 26, 2025   
    However, the introduction of HBV generic medications has lowered the cost of treatment for patients in the US. Future adoption of international reference pricing may help bridge remaining pricing disparities.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare, Vemlidy (tenofovir alafenamide) / Gilead
    Journal:  Second-Line Antiretroviral Therapy for Children Living with HIV in Africa. (Pubmed Central) -  May 14, 2025   
    Ritonavir-boosted darunavir was also effective. (Funded by the European and Developing Countries Clinical Trials Partnership and others; CHAPAS-4 ISRCTN Registry number, ISRCTN22964075.).
  • ||||||||||  Dovato (dolutegravir/lamivudine) / ViiV Healthcare, lamivudine / Generic mfg., Tivicay (dolutegravir) / ViiV Healthcare
    Review, Journal:  Two-drug regimen with dolutegravir plus lamivudine for HIV treatment in children: a narrative review. (Pubmed Central) -  May 2, 2025   
    The review highlights the need for further research to support the use of 2DR in children and adolescents, particularly regarding long-term safety and efficacy. With increasing focus on quality of life and affordability, the integration of 2DR into pediatric HIV care may represent a critical advance in improving treatment outcomes for this vulnerable population and warrants continued clinical investigation and careful implementation into practice.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Journal:  Antiretroviral-Induced Toxicity in Umbilical Cord Blood-Derived Haematopoietic Stem/Progenitor Cells. (Pubmed Central) -  Apr 28, 2025   
    Dolutegravir (DTG) had a biphasic effect on HSPC expansion...Finally, using colony forming unit (CFU) assays, we observed impairment in the formation of CFU-GEMM and CFU/Burst forming unit (BFU) erythroid (E) in the presence of DTG, lamivudine (3TC) and TDF, both visually and immunophenotypically. We conclude that multiple potential HSPC toxicities exist with ARVs commonly used in pregnancy, prompting the need for further research to confirm the safety of these drugs in this vulnerable group.
  • ||||||||||  lamivudine / Generic mfg.
    Trial primary completion date:  Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov) -  Apr 25, 2025   
    P2,  N=28, Recruiting, 
    We conclude that multiple potential HSPC toxicities exist with ARVs commonly used in pregnancy, prompting the need for further research to confirm the safety of these drugs in this vulnerable group. Trial primary completion date: Jul 2025 --> Oct 2025
  • ||||||||||  metformin / Generic mfg., lamivudine HBV / Generic mfg., lamivudine / Generic mfg.
    Preclinical, Journal:  Impact of metformin on HBV replication: No evidence of suppression in vitro. (Pubmed Central) -  Apr 11, 2025   
    In HepAD38 cells, HBV replication is not impacted by metformin treatment. This contrasts with prior in vitro data but is in line with clinical evidence that suggests metformin acts through an influence on liver disease progression rather than a direct antiviral impact on HBV itself.
  • ||||||||||  lamivudine HBV / Generic mfg., lamivudine / Generic mfg.
    Journal:  Design, Synthesis, and Bioevaluation of Matrine Derivatives as Potential Anti-Hepatitis B Virus Agents. (Pubmed Central) -  Mar 28, 2025   
    Of these, eleven compounds inhibited HBeAg secretion significantly more than the positive control, lamivudine (3TC)...These compounds inhibited viral gene expression and viral propagation in a cell culture model. Thus, we believe our compounds could serve as resource for antiviral drug development.
  • ||||||||||  lamivudine / Generic mfg.
    P2a data, Journal:  A Phase IIa clinical trial to evaluate the effects of anti-retroviral therapy in Alzheimer's disease (ART-AD). (Pubmed Central) -  Mar 19, 2025   
    P1/2
    The reverse transcriptase inhibitor 3TC (lamivudine) reduces retrotransposon activation and suppresses tau neurotoxicity among model systems...In addition to a favorable safety profile and stable cognitive measures, notable significant changes in fluid-based biomarkers include reduction of glial fibrillary acidic protein (GFAP) (P?=?0.03) in CSF, suggestive of reduced neuroinflammation, and elevation of A?42/40 (P?=?0.009) in plasma, suggestive of reduced plaque load in the brain. These results warrant further exploration in a larger, placebo-controlled trial.
  • ||||||||||  Invirase (saquinavir) / Roche, Viracept (nelfinavir) / ViiV Healthcare, Roche
    Trial completion, Trial completion date, Trial primary completion date:  A Prospective Cohort of Children With HIV Infection (clinicaltrials.gov) -  Mar 17, 2025   
    P=N/A,  N=500, Completed, 
    The findings provide valuable insights into ligand interactions, reactivity patterns, and the challenges associated with drug discovery in the context of the global pandemic. Trial completion date: Jun 2024 --> Sep 2024 | Trial primary completion date: Jun 2024 --> Sep 2024 | Active, not recruiting --> Completed
  • ||||||||||  lamivudine / Generic mfg.
    MODELING LATE-ONSET ALZHEIMER'S DISEASE NEUROPATHOLOGY VIA DIRECT NEURONAL REPROGRAMMING () -  Mar 10, 2025 - Abstract #ADPD2025ADPD_2298;    
    The findings demonstrate the feasibility and sufficiency of miRNA-induced directly converted LOAD neurons for modeling late-onset neuropathology of AD in a 3D environment. These neurons provide a platform to understand how aging influences vulnerability to late-onset neurodegeneration in LOAD patients.
  • ||||||||||  lamivudine HBV / Generic mfg.
    EVALUATING THE USE OF HEPATITIS B IMMUNOGLOBULIN POST LIVER TRANSPLANT (Halls C-E, Lower Level - SDCC) -  Mar 8, 2025 - Abstract #DDW2025DDW_4053;    
    These patients could be changed to tenofovir and have their HBIG ceased with monitoring as per protocol. This project demonstrates that patients receiving HBIG therapy should be more regularly reviewed for consideration of cessation in line with the guidelines.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Trends in HIV Viral Nonsuppression and Drug Resistance Among PWID on Dolutegravir ART in Kenya (Poster Hall) -  Mar 3, 2025 - Abstract #CROI2025CROI_1158;    
    This project demonstrates that patients receiving HBIG therapy should be more regularly reviewed for consideration of cessation in line with the guidelines. The odds of non-suppression for those on methadone versus not on methadone were 0.53 (p<0.05), for those living in improvised shelter/in the open versus those living at home/with a relative were 2.72 (p <0.01) and were reduced by 6% (p <0.001) per year of increased age...Resistance to NNRTIs was common (~30-45% at each visit), but major resistance to drugs in their DTG-based regimens was relatively infrequent, with resistance to tenofovir in 4/93 (4%), lamivudine in 7/93 (8%) and major DTG resistance in 2/93 (2%) participants only observed as minority variants
  • ||||||||||  Vemlidy (tenofovir alafenamide) / Gilead
    Body Composition Changes in People With HIV Switching From or Maintaining TDF-Based Regimens (Poster Hall) -  Mar 3, 2025 - Abstract #CROI2025CROI_958;    
    Background Weight gain might occur in people with HIV (PWH) switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF)-based antiretroviral therapy (ART), but data regarding body composition are missing...In the switching groups, time 1 (T1) was the date of switching to TAF (group 2) or abacavir (ABC) and/or lamivudine (3TC)-based ART (group 3), while in PWH who maintained TDF (group 1) was the closest date to other two groups...Trends over time for BC changes among the groups is shown in Table 1. Conclusions After 2 years of follow-up, maintaining TDF was associated with decrease in BMI and total lean mass, suggesting that weight loss observed with TDF regimens might be related to unhealthy lean loss.
  • ||||||||||  rifampicin / Generic mfg.
    TAF Achieves Adequate Intracellular Tenofovir-DP Concentrations With Rifampicin-Based TB Therapy (Poster Hall) -  Mar 3, 2025 - Abstract #CROI2025CROI_877;    
    Background Co-administration of rifampicin with tenofovir alafenamide fumarate (TAF) significantly reduces plasma tenofovir and intracellular tenofovir diphosphate (TFV-DP) concentrations...TAF and TDF were dosed at the standard daily doses (25 mg and 300 mg respectively) and were combined with efavirenz (600 mg), and either emtricitabine (200 mg) or lamivudine (300 mg)...Conclusions TAF and RIF co-administration was associated with higher TFV-DP concentrations than TDF, both with and without RIF. This study confirms previous findings among healthy volunteers and supports the co-administration of standard-dose TAF with RIF in the management of people with TB/HIV-1 co-infection.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Effect of Antiretroviral Regimen on Contraceptive Failure Among Women Using Injectable Contraception (Poster Hall) -  Mar 3, 2025 - Abstract #CROI2025CROI_722;    
    Conclusions In a population of WLWH who were taking DMPA as prescribed, we found a higher-than-expected pregnancy rate and potentially an elevated pregnancy rate with continuous efavirenz-based ART versus dolutegravir-based ART use. Further understanding of the causes of contraceptive failure among WLWH who use DMPA and ART is essential.
  • ||||||||||  Prezista (darunavir) / J&J, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
    Risk of Incident Hypertension With Common Antiretroviral Agent Combinations in the OPERA Cohort (Poster Hall) -  Mar 3, 2025 - Abstract #CROI2025CROI_589;    
    We estimated adjusted incidence rate ratios (aIRR; multivariate Poisson regression) comparing regimens of dolutegravir (DTG) 3DR with or without tenofovir alafenamide (TAF), DTG/lamivudine (3TC) 2DR, bictegravir/emtricitabine/TAF (B/F/TAF), or boosted darunavir (bDRV) 3DR with or without TAF. Conclusions In this real-world assessment of people with HIV with either n+eBP or nBP at regimen start, no statistically significant difference was observed between common core ARV agents with or without TAF and the rate of incident HTN in ART-na
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    24-Month Outcomes on Second-Line Antiretroviral Therapy in South Africa: A Target Trial Emulation (Poster Hall) -  Mar 3, 2025 - Abstract #CROI2025CROI_525;    
    Background The WHO recommends dolutegravir (DTG) instead of ritonavir-boosted lopinavir (LPV/r) in second-line antiretroviral therapy (ART), and recycled tenofovir disoproxil fumarate (TDF)/emtricitabine or lamivudine (XTC) instead of zidovudine (AZT)/XTC as backbone...We emulated a target trial among adults switching to second-line AZT/XTC/LPV/r, AZT/XTC/DTG, or TDF/XTC/DTG between December 2019 and February 2021 after viral failure with TDF/XTC/efavirenz...Conclusions Compared with AZT/XTC/LPV/r, people on second-line DTG had less viraemia, with no evidence of worse viraemia with recycled TDF. Interventions to improve LTFU and viraemia with second-line therapy are needed, and drug resistance surveillance remains essential.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Impact of ART Simplification With Dolutegravir and Lamivudine on the HIV Reservoir (Poster Hall) -  Mar 3, 2025 - Abstract #CROI2025CROI_520;    
    Conclusions Switching to DTG/3TC maintained plasma viral load suppression, didn't measurably impact HIV persistence markers in blood or tissue, and reduced systemic inflammation. These findings support the use of DTG/3TC in people living with HIV.
  • ||||||||||  Prezista (darunavir) / J&J, Descovy (emtricitabine/tenofovir alafenamide) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
    Genotypic Resistance in the African Paediatric CHAPAS-4 Trial of Second-Line Antiretroviral Therapy (San Francisco Ballroom A) -  Mar 3, 2025 - Abstract #CROI2025CROI_151;    
    Background In the CHAPAS-4 trial of second-line antiretroviral therapy following NNRTI-based first-line, 96-week efficacy was superior for tenofovir alafenamide (TAF) vs standard-of-care (SOC: abacavir (ABC)/zidovudine (ZDV)), and for dolutegravir (DTG) vs ritonavir-boosted lopinavir (LPV/r)/atazanavir (ATV/r)...Methods Randomisation was simultaneously to TAF vs ABC/ZDV, and DTG vs darunavir (DRV/r) vs LPV/r vs ATV/r...Intermediate/high-level resistance to anchor was: 0/29 LPV/r, 4% (1/26) ATV/r (1 TAF/FTC), 0/18 DRV/r and 22% (2/9) DTG (2 ZDV/3TC)...Three children on ZDV/3TC (2 DTG,1 LPV/r) developed new high-level emtricitabine/lamivudine (FTC/3TC) resistance (M184V)...W96 intermediate/high-level anchor drug resistance was uncommon, and as in second-line adult and paediatric trials, resistance to DTG only occurred in children taking ZDV. These results will inform second-line treatment guidelines for children.
  • ||||||||||  Prezista (darunavir) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
    Trial completion:  Body Composition Sub-study of the D2EFT Trial (clinicaltrials.gov) -  Jan 9, 2025   
    P4,  N=155, Completed, 
    Patients receiving 3TC/DTG showed higher plasma HDL-C levels compared with those on B/F/TAF, which confer long-term clinical benefits in reducing cardiovascular risk. Active, not recruiting --> Completed